Skip to Content

Liptruzet Approval History

  • FDA approved: Yes (First approved May 3rd, 2013)
  • Brand name: Liptruzet
  • Generic name: atorvastatin and ezetimibe
  • Dosage form: Tablets
  • Company: Merck
  • Treatment for: High Cholesterol, Familial Heterozygous

Liptruzet (atorvastatin and ezetimibe) is a statin (HMG-CoA reductase inhibitor) and cholesterol absorption inhibitor combination indicated for the treatment of hyperlipidemia.

Development History and FDA Approval Process for Liptruzet

May  3, 2013Approval FDA Approves Merck‚Äôs Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol
Jan  3, 2013Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.